Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration

Case report: Pharmacokinetics of pembrolizumab in a patient with stage IV non–small cell lung cancer after a single 200 mg administration

BackgroundPembrolizumab is a well-tolerated biologic agent with a potentially stable and durable anti-tumor response. Unfortunately, discontinuation of therapy can occur as a consequence of immune-related adverse effects (irAEs). These irAEs appear independent of dose and exposure. However, such irA...

Full description

Bibliographic Details
Main Authors: Fenna de Vries, Adrianus A. J. Smit, Gertjan Wolbink, Annick de Vries, Floris C. Loeff, Eric J. F. Franssen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
pembrolizumab
immunotherapy
immune-related adverse events
programmed cell death protein 1 (PD-1)
pharmacodynamic (PD)
pharmacokinetic (PK)
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.960116/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.960116/full

Similar Items